Fananserin (RP-62203) is a drug which acts as a potent antagonist at both the 5HT2A receptor,[1] and the Dopamine D4 receptor,[2] but without blocking other dopamine receptors such as D2.[3] It has sedative[4] and antipsychotic effects, and has been researched for the treatment of schizophrenia,[5] although efficacy was less than expected and results were disappointing.[6]
Clinical data | |
---|---|
Other names | Fananserin |
ATC code |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
IUPHAR/BPS |
|
ChemSpider |
|
UNII |
|
KEGG |
|
CompTox Dashboard (EPA) |
|
Chemical and physical data | |
Formula | C23H24FN3O2S |
Molar mass | 425.52 g·mol−1 |
3D model (JSmol) |
|
| |
| |
(what is this?) (verify) |